1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Markets for Orphan Drugs

Global Markets for Orphan Drugs

  • July 2021
  • 128 pages
  • ID: 96587
  • Format: PDF
  • BCC Research

Summary

Table of Contents

Report Scope:
The scope of this study includes orphan drugs used in the global pharmaceutical markets.This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry.

The report also analyzes each submarket and its applications, projections and market shares. Technological issues include the latest trends and developments.

This report covers the U.S. and European markets, and emerging global markets such as India, Japan, China, Singapore, Taiwan, Korea, Canada, Brazil, Africa, Australia and New Zealand.

This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases.The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources.

In addition, this report provides an overview of the global orphan drugs market and its competitive landscape.

Report Includes:
- 26 tables
- An updated review of the global markets for orphan drugs (ODs) within the healthcare industry
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of market size and revenue forecast for biological and non-biological orphan drugs, and corresponding market share analysis by product type, therapeutic category and geographic region
- Emphasis on the regulation of clinical trials on orphan designated drugs by leading regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) of Japan
- Review of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and Japan
- Discussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs exist
- Assessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areas
- Highlights of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact assessment and market share analysis of the top 20 manufacturers of orphan drugs
- Descriptive company profiles of the market leading participants, including AbbVie Inc., Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi-Aventis

Summary:
Orphan drugs have paved theway for the treatment of the many unmet clinical and therapeuticneeds of patientswith orphan and rare diseases such as Gaucher’s disease, Pompe disease, cystic fibrosis, Hunter syndrome, tuberous sclerosis complex and chronic myelogenous leukemia. These diseases, which have different globaldefinitions depending on theirprevalence in the general population, have gained significant attention since the approval of the 1983 OrphanDrug Act (ODA) in the U.S. and the formation of organizations such as the National Organization forRare Diseases (NORD) in 1983 and the EuropeanOrganization forRare Diseases (EURORDIS) in 1997. These developments have spurred
pharmaceutical and biotech companies such as Roche,Novartis, GlaxoSmithKline, Johnson&Johnson, Bristol-Myers Squibb,Merck& Co, Pfizer, Shire and others to invest in and develop orphan and rare disease therapies and drugs.

The orphan drug market has emerged as a niche business of the pharmaceutical industry.This market’s primary growth factors include incentives for orphan drug sponsors, tax breaks,market exclusivity, grants programs for clinical studies, funds for the development of orphan products andmultiple indication approvals.

The unveiling of the human genetic code,which created a betterunderstanding of humanmetabolismand the role of genetics in the manifestation of disease, also played a significant role in the development of the orphan drugmarket.

By region, the U.S. dominates the global orphan drugmarket due to growth factors such as advanced healthcare infrastructure and the U.S. Food and Drug Administration (FDA)-sponsored grant programs for the development of potential therapeutic compounds through itsOffice ofOrphan Products Development (OOPD). The Europeanmarket,with itswell-established orphan drug legal framework, also is expanding.Growth factors include multiple post-market safety and efficacy clinical trials and the commission of potentialorphan drugs through patient networks such as the EuropeanOrganization for Rare Diseases (EURORDIS).

The Asian pharmaceutical market offers potentialas countries such as Japan, Taiwan and South Korea have implemented legal legislations akin to the U.S.OrphanDrug Act. The main growth factors in this emerging regional market are patient awareness programs, global connectivity through rare disease patient organizations and the availability of orphan drugs through joint collaborations.

The global orphan drug market reached REDACTED in 2020.This market should reach REDACTED and REDACTED in 2021 and 2026, respectively, achieving aCAGRof REDACTED during the forecast period.

Growth factors include the increased involvement of pharmaceutical companies in developing orphan drugs, the growing numberof newapprovals and the increased global availability of these drugs.

The biological orphan drug market reached REDACTED in 2020. This market is expected to reach REDACTED and REDACTED by 2021 and 2026, respectively, achieving a CAGRof REDACTED during the forecast period.Multiple orphan approvals for pre-existing drugs should boost this growth. The non-biological orphan drugmarket reached REDACTED in 2020. This market should reach REDACTED by 2026, growing at a CAGRof REDACTED during the forec ast period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Antiviral Therapeutics Market Research Report by Drug, by Therapy, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • € 4340
  • October 2021
  • 199 pages

Antiviral Therapeutics Market Research Report by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, and HIV Antiviral Drug), by Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, and Protease ...

  • World
  • Therapy
  • Antiviral
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on